FDA Approval & Chinese Patent

4 May 2006 07:02

Inditherm PLC04 May 2006 Press Release 4th May 2006 Inditherm plc ("Inditherm" or "The Company") US FDA Approval and Chinese Patent Inditherm plc (AIM: IDM), the provider of innovative heating solutions to thefood, industrial process, utility, medical, construction and sport industries,has been granted approval by the US Food and Drug Administration ('FDA') tomarket its patient warming systems in the USA. FDA approval opens the way for Inditherm Medical to enter the US market. Commenting on the approval, Nick Bettles, Medical Division Director atInditherm, said, "Although the approval process has taken some time to completewe are, however, delighted that we can now move forward our plans for the USmarket. We already have a number of potential distribution partners lined up,and therefore can start active promotion quickly. Given the importance of FDArecognition - not just in terms of US legislation, but also as reassurance topotential purchasers worldwide - we expect this new status to accelerate thegrowth of Inditherm's medical business." In a separate development, Inditherm is pleased to announce the granting, inApril, of a patent in China for its core conductive polymer technology. Thepatent runs for 20 years from December 1999 (the date of original filing). Commenting on both the FDA approval and the Chinese patent, Richard Harpum,Chief Executive Officer, said, "It is satisfying that both processes havefinally completed and that we can now leverage them in support of our globalsales drive: FDA approval unlocks an important revenue opportunity for ourMedical business in the US market; whilst the new patent both confirms andprotects the innovative nature of our core technology in China." - Ends - For further information contact: Inditherm plc Richard Harpum, CEO +44 (0) 1709 761000rharpum@indithermplc.com www.inditherm.com Abchurch Georgina Bonham / Justin Heath Tel: +44 (0)20 7398 7700georgina.bonham@abchurch-group.com www.abchurch-group.com Editors' Notes The US FDA approval relates to patient warming products for use in the operatingroom, recovery room (PACU), intensive care, and emergency department. Theneonatal warming products are subject to a separate FDA application. The patent concerned is no. ZL99815386.9, filed on 3 December 1999. Inditherm plc is an AIM-listed provider of low voltage, cost-effective heatingtechnology. It manufactures, installs and licenses its specialised heatingtechnology for use in numerous applications that require temperature maintenanceor frost protection, including industrial, utility, medical, construction, andsports turf heating. Inditherm's technology uses a carbon-based, electrically conductive polymer,also called Inditherm, to produce a cost-effective, flexible and adaptableheating surface that heats between ambient temperature and 120degreesC.Typically powered from a 6V to 48V (ac or dc) power supply, Inditherm generatesuniform heat over its entire surface with no hot spots. It can be shaped to fitover a wide variety of applications, making it highly adaptable. It is alsoideal for heating large flat areas, such as sports pitches. The Rotherham-based company now operates in a global environment and has ablue-chip customer base. It has patent protection in the USA and applicationspending across the EU and in many other countries. This information is provided by RNS The company news service from the London Stock Exchange